TBPH Theravance Biopharma Inc stock chart & analysis

Conviction 90HealthcareScan · Fri, Nov 6, 2026

Theravance Biopharma Inc (TBPH) closed at $17.03 on Nov 6, 2026. Price is above its 50-day and below its 200-day moving average. RSI(14) 53, RS Rating 84, -19.0% from its 52-week high, -9.0% year to date. Sector: Healthcare · Biotechnology.

TBPH$17.03

ResistanceSupportVol 14Insider sellCongress buyCongress sell

Loading chart…

Theravance Biopharma IncBiotechnologywww.theravance.com ↗

Price17.03

Change—

Gap+0.18%

Rel volume—

Avg volume1.18M

Avg $ vol20.14M

SMA 2017.04

SMA 5016.96

SMA 20017.18

Price vs 50+0.39%

Price vs 200-0.87%

MA stackmixed

50/200 cross—

Supertrendup · 16.95

RSI (14)53

MACD hist-0.01

MACD crossbear · 9d

Stoch %K / %D12 / 14

ADX (14)41

+DI / −DI25 / 10

RSI divergence—

MACD divergence—

ATR %0.33%

ADR %0.30%

52w high21.03

52w low13.08

From 52w high-19.02%

Above 52w low+30.20%

New 52w highNo

SqueezeOn · 42d

Bollinger width0.45%

%B0.34

Donchian pos11.76%

Donchian high17.26

Donchian low17.00

AVWAP (52w high)16.65

vs AVWAP high+2.28%

AVWAP (52w low)16.30

vs AVWAP low+4.48%

OBV trendDown

Chaikin MF (20)-0.60

Today vs 20d—

Avg vol (14d)1.48M

Avg vol (20d)1.18M

Avg $ vol (20d)20.14M

Market cap857.84M

RS Rating84 / 99

RS 3m (vs SPY)-6.10%

RS 6m (vs SPY)-3.25%

RS line new highNo

Trend template2/8

Technical rank70.5

1 week+0.00%

1 month+0.12%

3 months-1.39%

6 months+14.30%

1 year+21.04%

YTD-8.98%

P/E—

P/B—

P/S—

P/FCF—

EPS—

Div yield—

ROE—

ROA—

Debt/Eq—

Current—

EV/EBITDA—

Gross margin—

Net margin—

Rev growth—

EPS growth—

Price target—

Target upside—

Analyst rating—

Institutional—

Ent. value—

Revenue—

Net income—

Gross profit—

Free cash flow—

IndustryBiotechnology

ExchangeXNAS

Shares out51.55M

Employees90

ListedFri, May 16, 2014

Free float46.92M

Float %92.6%

Short interest—

Days to cover—

Short volume—

Squeeze score—

Next earnings—

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeA

Conviction90 / 100

Pattern quality—

Tech rank70.5 / 100

Group rank23 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance17.14

Support16.88

Days since event—

Candle confirm—

TBPH technical analysis

Trend

TBPH's moving averages are mixed — no clean uptrend or downtrend. It closed 0.4% above the 50-day ($16.96) and 0.9% below the 200-day ($17.18). ADX(14) at 41 points to a strong, established trend. It meets 2 of 8 trend-template criteria.

Momentum

RSI(14) is 53, in the bullish half of its range. MACD crossed below its signal line 9 sessions ago. Its RS Rating of 84 puts its weighted 12-month performance ahead of about 84% of the US market.

Volume and volatility

It trades about $20.1M a day on average. ATR(14) is $0.0555, 0.3% of price — its typical daily range. Bollinger Bands are in a squeeze (42 sessions) — volatility is compressed. On-balance volume is trending down. Chaikin Money Flow (-0.60) shows distribution.

Key levels

The chart pattern's support is $16.88 and its resistance $17.14. The 52-week range is $13.08 to $21.03; price is 19.0% below the high and 30.2% above the low. The VWAP anchored at the 52-week high is $16.65, below price.

Performance

TBPH returned +0.0% (1 week), +0.1% (1 month), -1.4% (3 months), +14.3% (6 months), +21.0% (1 year), -9.0% (year to date).

About Theravance Biopharma Inc

Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.

Biotechnology · Listed 2014 · 90 employees

Congress activity

Disclosed STOCK Act trades in TBPH · 1 recent

All disclosures →

Member	Side	Amount	Traded	Filed	PTR
George Whitesides house · D · CA · traded 2025-03-24	Sell	$15K–$50K	2025-03-24	2025-04-23	PDF

Insider activity

SEC Form 4 transactions in TBPH · open-market 5 sells

Insider	Side	Shares	Value	Traded	Filed
Farnum Rhonda SVP, COMM & MEDICAL AFFAIRS · Ordinary Shares · 2026-09-15	Sell	6.66K	$113K	2026-09-15	2026-09-17
Farnum Rhonda SVP, COMM & MEDICAL AFFAIRS · Ordinary Shares · 2026-09-15	Sell	3.33K	$57K	2026-09-15	2026-09-17
Farnum Rhonda SVP, COMM & MEDICAL AFFAIRS · Ordinary Shares · 2026-09-15	Sell	3.33K	$57K	2026-09-15	2026-09-17
Sawaf Aziz SVP & CHIEF FINANCIAL OFFICER · Ordinary Shares · 2026-08-20	Tax	8.11K	$137K	2026-08-20	2026-08-24
Winningham Rick E CHIEF EXECUTIVE OFFICER · Ordinary Shares · 2026-08-20	Tax	20.03K	$340K	2026-08-20	2026-08-24
Grimaud Brett A. SVP, GEN COUNSEL AND SECRETARY · Ordinary Shares · 2026-08-20	Tax	7.95K	$135K	2026-08-20	2026-08-24
Farnum Rhonda SVP, COMM & MEDICAL AFFAIRS · Ordinary Shares · 2026-08-20	Tax	5.67K	$96K	2026-08-20	2026-08-24
Miller Aine SVP, DEV & HEAD OF IRE OFFICE · Ordinary Shares · 2026-08-20	Tax	6.26K	$106K	2026-08-20	2026-08-24
Samaha Eli 10% owner · COM · 2026-07-07	Sell	5.56K	$96K	2026-07-07	2026-07-08
Samaha Eli 10% owner · COM · 2026-07-06	Sell	1.4K	$24K	2026-07-06	2026-07-08

SEC filings

EDGAR filings in TBPH · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.

Start free — 7-day trial, no card →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.